Navigation Links
BHR Pharma Files Investigational New Drug Application, Receives Orphan Drug Designation, for Traumatic Brain Injury Treatment
Date:12/8/2009

r biologics that treat a rare disease or condition affecting less than 200,000 Americans. The designation offers a number of incentives to the treatment developer. This includes a seven-year period of U.S. marketing exclusivity if the drug receives marketing authorization by the agency. Funding for clinical studies, study design assistance, waiver of FDA user fees and tax credits are additional potential incentives.

The company plans to request that the treatment be fast tracked during the regulatory approval process.

"Traumatic brain injury is a terrible condition with high rates of mortality and disability, and currently there are no drugs approved for treating these patients," said Tom MacAllister, BHR president and CEO. "We're excited about achieving the IND milestone and believe that the orphan status will help facilitate a development program with the potential to give these patients and their families hope for better quality of life."

About BHR

Founded in January 2008, BHR Pharma, LLC (www.bhr-pharma.com) is a pharmaceutical research and development (R&D) company located near Washington, DC. BHR is committed to bringing to market specialty treatments that employ non-oral delivery systems, with an emphasis on unmet and underserved medical needs.

A wholly owned subsidiary of Besins Healthcare SA (www.besins-healthcare.com), which markets healthcare products in 93 countries, BHR manages all of Besins' global R&D activities. Those activities primarily leverage proprietary parenteral drug formulations, including the Enhanced Hydroalcoholic Gel (EHG(R)) technology pioneered and commercially launched by Besins in 1975.

SOURCE BHR Pharma, LLC


'/>"/>
SOURCE BHR Pharma, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... obese and overweight American children and teens look in ... U.S. health officials reported Wednesday. "Being overweight or ... high blood pressure, high cholesterol and diabetes," said lead ... Centers for Disease Control and Prevention,s National Center for ...
(Date:7/23/2014)... Celebrating a decade of philanthropy in 2014, The ... of $1,070,000 in grants to 20 New Jersey non-profit ... Foundation’s 1,000th grant. , “The Horizon Foundation for New ... community-based organizations that are working to improve public health ... State,” said Robert A. Marino, Horizon Blue Cross Blue ...
(Date:7/23/2014)... Painful or itchy skin lesions could be a warning ... have multiple lesions that are suspicious looking, and those ... for non-melanoma skin cancers," study author Dr. Gil Yosipovitch, ... said in a Temple University Health System news release. ... patients who were confirmed to have skin cancer lesions ...
(Date:7/23/2014)... University in Shaanxi province, and the University of California, ... the groundwork for establishing the Sino-U.S. Joint Research Center ... was held in the city of Yingchuan, China, during ... of Agriculture and China,s Ministry of Science and Technology. ... Davis and for our World Food Center and serves ...
(Date:7/23/2014)... DC (PRWEB) July 23, 2014 ... for ATA 2015, ATA’s twentieth annual meeting and ... The meeting, expected to attract over 5,000 attendees ... will take place May 3-5, 2015, in Los ... most renowned healthcare technology professionals from researchers, clinicians, ...
Breaking Medicine News(10 mins):Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2
... Case Western Reserve University School of Medicine has developed ... lymphoblastic leukemia (ALL). ALL is the most common type ... each year in the United States. The findings provide ... development of "theranostic" agents-- a treatment platform that combines ...
... HealthDay Reporter , TUESDAY, March 6 (HealthDay News) ... stave off hot flashes, night sweats and other symptoms of ... down the road, a news study says. Hormone replacement ... government-run trial, the U.S. Women,s Health Initiative, was stopped early ...
... assistant professor of computer science and robotics engineering at ... CAREER Award from the National Science Foundation (NSF) to ... purpose robots that can work effectively and productively alongside ... WPI faculty members to receive the CAREER Award, the ...
... Mar 07, 2012-200 million teenagers suffer from depression ... results have led to increased controversy surrounding the ... on the latest research findings on antidepressant medications ... by Journal of Child and Adolescent Psychopharmacology (http://www.liebertpub.com/cap), ...
... at the University of Warwick have used state-of-the-art nuclear ... how pharmaceutical molecules pack together in the solid state. ... NMR magnets, housed at the University of Warwick, to ... and GlaxoSmithKline. The analytical methods look directly ...
... FRANCISCO March 6, 2012 A new paradigm to ... treatment advances that may ultimately vanquish the disease known as ... Ophthalmology , the journal of the American Academy of ... glaucoma solely as an eye disease. Instead, they view it ...
Cached Medicine News:Health News:Researchers develop first 'theranostic' treatment for acute lymphoblastic leukemia (ALL) 2Health News:Estrogen-Only Therapy May Reduce Breast Cancer Risk 2Health News:Estrogen-Only Therapy May Reduce Breast Cancer Risk 3Health News:Estrogen-Only Therapy May Reduce Breast Cancer Risk 4Health News:WPI's Sonia Chernova wins NSF CAREER award for work aimed at creating 'everyday' robots 2Health News:More effective treatments urgently needed for adolescent depression 2Health News:New research characterizes glaucoma as neurologic disorder rather than eye disease 2
(Date:7/23/2014)... , July 23, 2014 UBM Medica ... – a new online community and information resource for ... manage and treat their patients with neurological disorders ... with an aging population, necessitates greater access to dedicated ...  Key statistics on neurological conditions include: , ...
(Date:7/23/2014)... , July 23, 2014 Research and ... Electrocardiograph (ECG) Market by Product, End-user & by Lead ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... segmented into three major segments, namely, holter monitor, resting, ... was valued at $3,683 million in 2013 and is ...
(Date:7/23/2014)... /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid Services ... Improvement Organization (QIN-QIO) contract to a partnership led by ... August 1, WVMI will launch Quality Insights Quality Innovation ... Pennsylvania , Delaware , ... Network will engage providers and the community in multiple, ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Announcing a New Regional Approach to Medicare Quality Improvement 2
... using patented, innovative technology, measures a complete ... only 5 minutes from a simple fingerstick. ... get immediate liver function results. The scope ... only advantage to healthcare providers. The physician, ...
The Strep A Rapid Test Strip is a rapid chromatographic,immunoassay for the qualitative detection of Strep A antigen,from throat swab specimens to aid in the diagnosis of Group A,Streptococcal ...
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
Medicine Products: